U.K. pharmaceutical giant GSK on Tuesday struck a $10.6 billion deal to buy U.S.-listed biotech company Nuvalent, its biggest acquisition in eight years as it seeks to bolster the cancer portfolio it had previously trimmed.
GSK just announced its biggest purchase in eight years to rev up cancer portfolio it had previously wound down
Related Posts
Popular News
-
Cash usage shrinks to below 10% for first time on record as Britons turn to mobile phones to make payments
-
NerdWallet’s Best-Of Credit Card Awards: What’s New for Class of 2025?
-
ELTIF boom gathers pace following EU reg changes
-
How to Contact Hilton Customer Service
-
Matching Sets Are the Ultimate Summer Travel Hero—Here Are 15 Styles Worth Packing
Latest News
The Most Extravagant Hotel Packages for Soccer Fans Heading to New Jersey World Cup Games
The Penthouse World Cup Package at The Mark—one of the most iconic hotels on the Upper East Side—is definitely the...
GM follows Ford by making a big energy bet — this time with an unconventional approach
GM plans to revamp its energy business and place a big bet on sodium-ion batteries just as shares of rival...
Wintermute warns Bitcoin lacks inflows needed to confirm market bottom
Bitcoin’s recent selloff has yet to establish a durable market bottom as institutional demand remains absent and capital continues to...
LePage wins Maine Republican nod in key US House battleground
LePage wins Maine Republican nod in key US House battleground
Welcome to Global Finances Daily, your go-to source for all things finance. Our mission is to provide our readers with valuable information and insights to help them achieve their financial goals and secure their financial future.